Evidence map›Paper›PMID 36709185›Full record

Trial reportZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2022

[Bendamustine monotherapy for Chinese patient treatment with relapsed or refractory B cell non-Hodgkin lymphoma: a phase Ⅱ, prospective, multicenter, single-arm study].

Y Gao, Y Yang, H Cen, H Liu, J X Fu, S Q Wang, R Feng, D Yu, X Y Zhang, Z W Chen and 2 more

Open access · greenAbstract readClinical Trial, Phase IIMulticenter StudyEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 73% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Y GaoDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, and Collaborative Innovation Center of Cancer Medicine,Guangzhou 510060, China.
Y YangDepartment of Lymphoma and Head and Neck Cancer, Fujian Tumor Hospital, Affiliated Cancer Hospital of Fujian Medical University, Fuzhou 350014, China.
H CenDepartment of Chemotherapy, Guangxi Cancer Hospital and of Guangxi Medical University Affiliated Cancer Hospital, Nanning 530021, China.
H LiuDepartment of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, China.
J X FuThe Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
S Q WangDepartment of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510000, China.
R FengDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
D YuOncology Medicine Department, Hubei Cancer Hospital, Wuhan 430079, China.
X Y ZhangDepartment of Hematology, The Second Clinical Medical College (Shenzhen People's Hospital) , Jinan University, Shenzhen 518020, China.
Z W ChenDepartment of Hematology, The First People's Hospital of Foshan, Foshan 528000, China.
Y F LiDepartment of Hematology, Henan Cancer Hospital, Henan Institute of Hematology, Zhengzhou 450008, China.
H Q HuangDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, and Collaborative Innovation Center of Cancer Medicine,Guangzhou 510060, China.
Nanfang Hospital · CNNantong University · CNSecond Affiliated Hospital of Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bendamustine HydrochlorideLymphoma, B-CellNeoplasm Recurrence, LocalAdultAgedChinaHumansMiddle AgedNeutropeniaProspective StudiesThrombocytopeniaYoung AdultBendamustine HydrochlorideBendamustineLymphoma, B-cellSafetyTreatment outcome

Identifiers

PMID36709185
PMCPMC9808866
OpenAlexW4318451016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.